NCT05647512 2023-11-18
Study of LM-305 in Patients With Relapsed or Refractory Multiple Myeloma (RRMM) and Other Plasma Cell Diseases
LaNova Medicines Limited
Phase 1/2 Withdrawn
Clinical Trials
9 trialsNCT02389543 2023-01-26
SLAM
Karyopharm Therapeutics Inc
Phase 1/2 Withdrawn
NCT00995059 2023-01-05
Bortezomib Before Donor Stem Cell Transplant in Treating Patients With Multiple Myeloma
Mayo Clinic
Phase 1/2 Withdrawn
NCT03856112 2019-03-26
Ixazomib and Dexamethasone With or Without Venetoclax in Treating Patients With Non-t(11;14) Relapsed or Refractory Multiple Myeloma
National Cancer Institute (NCI)
Phase 1/2 Withdrawn
NCT03100877 2017-12-13
Melphalan, Total Marrow Irradiation, and Autologous Stem Cell Transplantation in Treating Patients With High-Risk Multiple Myeloma
City of Hope Medical Center
Phase 1/2 Withdrawn
NCT03191981 2017-08-24
MUKfourteen
University of Leeds
Phase 1/2 Withdrawn
NCT02802163 2017-04-25
Induction Therapy for Multiple Myeloma With Carfilzomib, Lenalidomide,Dexamethasone,Panobinostat
H. Lee Moffitt Cancer Center and Research Institute
Phase 1/2 Withdrawn
NCT02605356 2016-10-07
Phase 1b/2 Study Testing Radium-223 Dichloride/Bortezomib/Dexamethasone Combination in Relapsed Multiple Myeloma
Bayer
Phase 1/2 Withdrawn
NCT02115035 2014-08-27
A Single Agent Study to Evaluate the Overall Response Rate, Safety and Tolerability of Orally Administered Vemurafenib
University of Arkansas
Phase 1/2 Withdrawn